Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Total Non-Current Liabilities (2023 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $1.7 million as the latest value for Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 40.51% to $1.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Jan 2026, up 40.51% year-over-year, with the annual reading at $2.9 million for FY2025, 69.4% down from the prior year.
  • Total Non-Current Liabilities for Q1 2026 was $1.7 million at PharmaCyte Biotech, down from $3.3 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $11.6 million in Q4 2024, with the low at $586581.0 in Q2 2023.
  • Average Total Non-Current Liabilities over 4 years is $5.4 million, with a median of $4.0 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 1537.5% in 2024, then tumbled 89.11% in 2025.
  • Over 4 years, Total Non-Current Liabilities stood at $9.3 million in 2023, then grew by 25.12% to $11.6 million in 2024, then tumbled by 71.92% to $3.3 million in 2025, then plummeted by 48.68% to $1.7 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $1.7 million, $3.3 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.